Usefulness of preoperative multidetector-row computed tomography in evaluating the extent of invasive lobular carcinoma in patients with or without neoadjuvant chemotherapy

BackgroundThe present study was conducted to assess the clinical usefulness of multidetector-row CT (MDCT) in determining the extent of invasive lobular carcinoma (ILC) and especially the extent of residual tumor after neoadjuvant chemotherapy (NAC).Patients and methodsThe subjects were 24 patients with primary ILC who underwent surgery without NAC and 17 patients with ILC who underwent surgery after NAC at National Cancer Center Hospital (NCCH) between April 1999 and December 2005. The extent of primary ILC was assessed by ultrasound, mammography, and MDCT before surgery, and the results obtained using each modality were compared with the results of pathological examination after surgery. In addition, the characteristic findings of ILC obtained by MDCT were assessed. Similarly, the extent of residual tumor after NAC was evaluated using ultrasound, mammography, and MDCT before surgery in the subjects who underwent NAC, and the results obtained by each modality were compared with the results of pathological examination after surgery.ResultsThe findings of primary ILC obtained by MDCT showed that the carcinoma was the non-localized type rather than the localized type in 63% of the subjects. In addition, with regard to the pattern of time-sequential contrast enhancement, the persistent pattern (in which tumor enhancement is strong in the late phase rather than in the early phase) was observed in 46% of the subjects, and the plateau pattern (in which contrast enhancement is weak in both the early phase and the late phase) was observed in 38% of the subjects. These trends were significant in the subjects who underwent NAC and in whom tumor enhancement could not be clearly observed by MDCT. Assessment of the extent of carcinoma showed that the diagnostic accuracy of MDCT was 79%, as compared with 71% for either ultrasound or mammography. Assessment of the extent of carcinoma after NAC also showed that the diagnostic accuracy of MDCT was 71%, as compared with 48% for ultrasound and 53% for mammography, indicating that MDCT provided the highest accuracy. It should be noted that for all modalities, the extent of ILC was not overestimated as compared with the tumor diameter measured during pathological examination.ConclusionAssessment by MDCT showed that ILC tends to be diffuse, tumor enhancement tends to be very weak, and the rate of enhancement tends to be low. In addition, MDCT was found to be useful for determining the extent of carcinoma, and the diagnostic accuracy of MDCT, especially in determining the extent of carcinoma after NAC, was much higher than that of ultrasound or mammography.

[1]  Anna L. Brown,et al.  Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Mark A. Helvie,et al.  Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy , 2005, Breast Cancer Research and Treatment.

[3]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Izuo,et al.  The general rules for clinical and pathological recording of breast cancer , 1989, The Japanese journal of surgery.

[5]  Computed-tomographic features of invasive lobular carcinoma. , 2005, Clinical imaging.

[6]  P. Drew,et al.  Dynamic contrast enhanced magnetic resonance imaging aids the surgical management of invasive lobular breast cancer. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[7]  S. Singletary,et al.  Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.

[8]  S. Akashi-Tanaka,et al.  The Use of Contrast-Enhanced Computed Tomography Before Neoadjuvant Chemotherapy to Identify Patients Likely to Be Treated Safely With Breast-Conserving Surgery , 2004, Annals of surgery.

[9]  L. Brunereau,et al.  Contrast enhanced magnetic resonance imaging underestimates residual disease following neoadjuvant docetaxel based chemotherapy for breast cancer. , 2004, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[10]  C. Zuiani,et al.  Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.

[11]  Dianne Georgian-Smith,et al.  Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.

[12]  A. D. De Schepper,et al.  Preoperative breast MRI in patients with invasive lobular breast cancer , 2004, European Radiology.

[13]  P. Chérel,et al.  Response to neoadjuvant chemotherapy in lobular and ductal breast carcinomas: a retrospective study on 860 patients from one institution. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  H. Tsuda,et al.  Accuracy of contrast‐enhanced computed tomography in the prediction of residual breast cancer after neoadjuvant chemotherapy , 2001, International journal of cancer.

[15]  T Kumazaki,et al.  Radiographic features of invasive lobular carcinoma of the breast. , 2001, Radiation medicine.

[16]  M. Kerin,et al.  Radial scars/complex sclerosing lesions and malignancy in a screening programme: incidence and histological features revisited , 2007, Histopathology.

[17]  Amy Berrington de González,et al.  Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries , 2004, The Lancet.

[18]  L. Bonomo,et al.  MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. , 2006, Clinical Radiology.

[19]  J. Margenthaler,et al.  Correlation between core biopsy and excisional biopsy in breast high-risk lesions. , 2006, American journal of surgery.

[20]  P. Blondeel,et al.  Different responses to preoperative chemotherapy for invasive lobular and invasive ductal breast carcinoma. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[21]  S. Singletary,et al.  Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2006, Annals of Surgical Oncology.

[22]  Rebecca S Lewis,et al.  Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. , 2004, Radiology.

[23]  Yoshinobu Sato,et al.  Preoperative Evaluation of Residual Tumor Extent by Three‐Dimensional Magnetic Resonance Imaging in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy , 2006, The breast journal.